4 6 6 4 3

论文已发表


注册即可获取德孚的最新动态



IF 收录期刊












更多详情 >>



停止接受任何荟萃分析文章 (Meta-analysis)

请注意:我们所有期刊已于 2019 年 4 月 1 日停止接受任何荟萃分析 (Meta-analysis)文章的提交。


会员计划

我们很高兴为机构提供一种切实的方法以支持开放获取并鼓励教师和研究人员通过开放获取模式尽可能广泛地传播他们的作品。

更多详情 >>

 

视频

Elevated serum levels of vascular endothelial growth factor predict a poor prognosis of platinum-based chemotherapy in non-small cell lung cancer

 

Authors Zang JL, Hu Y, Xu XY, Ni J, Yan DL, Liu SW, He J, Xue J, Wu JZ, Feng JF

Received 7 October 2016

Accepted for publication 6 December 2016

Published 18 January 2017 Volume 2017:10 Pages 409—415

DOI https://doi.org/10.2147/OTT.S124124

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Manfred Beleut

Peer reviewer comments 3

Editor who approved publication: Dr Ingrid Espinoza

Aim: This study was designed to investigate the predictive and prognostic values of serum vascular endothelial growth factor (VEGF) level in non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Methods: Patients’ peripheral blood samples were collected prior to chemotherapy and after 1 week of the third cycle of combination chemotherapy. Serum VEGF levels were evaluated through Luminex multiplex technique. Between September 2011 and August 2015, a total of 135 consecutive advanced or recurrent histologically verified NSCLC patients were enrolled in the study. Moreover, all the patients received platinum-based combination chemotherapy as a first-line treatment.
Results: No significant associations were found between pretreatment serum VEGF levels and clinical characteristics, such as sex (=0.0975), age (=0.2522), stage (=0.1407), lymph node metastasis (=0.6409), tumor location (=0.3520), differentiated degree (=0.5608), pathological (histological) type (=0.4885), and response to treatment (=0.9859). The VEGF load per platelet (VEGF
PLT) levels were not correlated with sex, age, primary tumor site, and pathological type in NSCLC patients (all >0.05). The median survival time of progression-free survival (PFS) was 6.407 and 5.29 months in the low and high groups, respectively, when using 280 pg/mL VEGF level as the cutoff point (=0.024).
Conclusion: In conclusion, the serum VEGF levels were found to be a poor prognostic biomarker for the efficacy of platinum-based chemotherapy in terms of PFS, but it was not shown to be a suitable predictive marker for clinical response to platinum-based chemotherapy.
Keywords: non-small cell lung cancer, VEGF, progression-free survival, platinum, chemotherapy, Luminex multiplex, prognosis


摘要视频链接Serum VEGF predicts a poor prognosis in NSCLC